The 8 analysts offering 12-month price forecasts for Royalty Pharma PLC have a median target of 53.00, with a high estimate of 58.00 and a low estimate of 48.00. The median estimate represents a +34.08% increase from the last price of 39.53.
The current consensus among 10 polled investment analysts is to Buy stock in Royalty Pharma PLC. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share $0.80
Reporting Date Aug 17
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.